Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy

Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy

Abstract Background Malignant angiomyolipoma is an uncommon tumor of the class of perivasciular epithelioid cell neoplasms (PEComas). These tumors are characteristically driven by deleterious mutations in the tumor suppressors TSC1 and TSC2, whose gene products typically act to inhibit mTOR. There a...

Full description

Bibliographic Details
Main Authors: Michael Lattanzi, Fang-Ming Deng, Luis A. Chiriboga, Alisa N. Femia, Shane A. Meehan, Gopa Iyer, Martin H. Voss, Yuliya Sundatova, William C. Huang, Arjun V. Balar
Format: Article
Language:English
Published: BMJ Publishing Group 2018-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immunotherapy
Angiomyolipoma
PEComa
Nivolumab
PD-1
PD-L1
Online Access:http://link.springer.com/article/10.1186/s40425-018-0415-x

Internet

http://link.springer.com/article/10.1186/s40425-018-0415-x

Similar Items